UA84141C2 - Применение ингибитора пктжк для лечения или профилактики запора - Google Patents

Применение ингибитора пктжк для лечения или профилактики запора

Info

Publication number
UA84141C2
UA84141C2 UAA200508758A UA2005008758A UA84141C2 UA 84141 C2 UA84141 C2 UA 84141C2 UA A200508758 A UAA200508758 A UA A200508758A UA 2005008758 A UA2005008758 A UA 2005008758A UA 84141 C2 UA84141 C2 UA 84141C2
Authority
UA
Ukraine
Prior art keywords
iват
constipation
prophylaxis
inhibitor
treatment
Prior art date
Application number
UAA200508758A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хассе Роланд АБРАХАМССОН
Пер-Горан ГИЛЛБЕРГ
Original Assignee
Альбирео Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9956272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA84141(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Альбирео Аб filed Critical Альбирео Аб
Publication of UA84141C2 publication Critical patent/UA84141C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Изобретение относится к применению ингибитора подвздошно-кишечного транспорта желчных кислот (ПКТЖК) или его фармацевтически приемлемой соли, сольвата, сольвата такой соли или пролекарств; фармацевтической композиции названных соединений в сочетании с фармацевтически приемлемым разбавителем или носителем для получения препарата, применяемого для лечения и/или профилактики запора.
UAA200508758A 2003-04-05 2004-04-01 Применение ингибитора пктжк для лечения или профилактики запора UA84141C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307918.3A GB0307918D0 (en) 2003-04-05 2003-04-05 Therapeutic use
PCT/GB2004/001396 WO2004089350A1 (en) 2003-04-05 2004-04-01 Use of an ibat inhibitor for the treatment of prophylaxis of constipation

Publications (1)

Publication Number Publication Date
UA84141C2 true UA84141C2 (ru) 2008-09-25

Family

ID=9956272

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200508758A UA84141C2 (ru) 2003-04-05 2004-04-01 Применение ингибитора пктжк для лечения или профилактики запора

Country Status (33)

Country Link
US (1) US7514421B2 (ru)
EP (2) EP1894564B1 (ru)
JP (2) JP4870552B2 (ru)
KR (1) KR101321577B1 (ru)
CN (1) CN100366241C (ru)
AR (1) AR043985A1 (ru)
AT (2) ATE387194T1 (ru)
AU (1) AU2004228731B2 (ru)
BR (1) BRPI0408858A (ru)
CA (1) CA2520109C (ru)
CO (1) CO5640076A2 (ru)
CY (2) CY1107424T1 (ru)
DE (1) DE602004012079T2 (ru)
DK (2) DK1610770T3 (ru)
ES (2) ES2299832T3 (ru)
GB (1) GB0307918D0 (ru)
HK (1) HK1085666A1 (ru)
IL (1) IL170913A (ru)
IS (1) IS8113A (ru)
MX (1) MXPA05010706A (ru)
MY (1) MY137757A (ru)
NO (1) NO335140B1 (ru)
NZ (1) NZ542835A (ru)
PL (2) PL1894564T3 (ru)
PT (2) PT1894564E (ru)
RU (2) RU2342928C2 (ru)
SA (1) SA04250066B1 (ru)
SI (2) SI1894564T1 (ru)
TW (1) TWI338577B (ru)
UA (1) UA84141C2 (ru)
UY (1) UY28258A1 (ru)
WO (1) WO2004089350A1 (ru)
ZA (1) ZA200507996B (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
CA2679314A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory conditions
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN103260625B (zh) 2010-11-08 2016-01-06 阿尔比里奥公司 用于治疗肝脏疾病的ibat抑制剂
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
JP2016514678A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR101420315B1 (ko) * 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
CN106659726A (zh) * 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CA2995798A1 (en) 2015-08-17 2017-02-23 Nipul Ghanshyambhai PATEL Liquid formulations containing picosulfate and magnesium citrate
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
DK3643718T3 (da) 2017-06-20 2023-11-06 Takeda Pharmaceuticals Co Heterocyklisk forbindelse og anvendelse deraf som positiv allosterisk modulator af den kolinerge muskarin m1-receptor
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
BR112020017353A2 (pt) 2018-03-09 2020-12-15 Elobix Ab Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
TWI823954B (zh) 2018-06-20 2023-12-01 瑞典商艾爾比瑞歐公司 奧德維希百(odevixibat)之結晶修飾物
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AU2020223022A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022166680A1 (zh) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 奥德昔巴特的晶型及其制备方法和用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO170760C (no) 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
NZ240846A (en) 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
ATE175954T1 (de) 1991-10-17 1999-02-15 Shionogi & Co Verfahren zum herstellen von lignin-analoga und ausgangsprodukte dafür
FI108451B (fi) 1991-12-20 2002-01-31 Hoechst Ag Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi
JPH05186357A (ja) * 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ES2111092T3 (es) 1992-06-12 1998-03-01 Hoechst Ag Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
WO1994024087A1 (en) 1993-04-16 1994-10-27 Shionogi & Co., Ltd. Process for producing lignan compound
TW289021B (ru) 1993-05-08 1996-10-21 Hoechst Ag
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (ru) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
ATE199718T1 (de) 1994-09-13 2001-03-15 Monsanto Co Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate- aufnahme
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
DE69734100D1 (de) 1996-03-11 2005-10-06 G D Searle Llc St Louis Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
WO1998007749A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
NZ337830A (en) 1997-03-11 2001-07-27 G Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
EP0864582B1 (en) 1997-03-14 2003-06-04 Aventis Pharma Deutschland GmbH Hypolipidemic 1,4-benzothiazepine-1,-dioxides
PT869121E (pt) 1997-04-04 2004-10-29 Aventis Pharma Gmbh Derivados de propanolamina hipolipidemicos
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO1998056757A1 (fr) 1997-06-11 1998-12-17 Sankyo Company, Limited Derives de benzylamine
AUPO763197A0 (en) 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
WO1999032478A1 (en) 1997-12-19 1999-07-01 G.D. Searle & Co. Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845406C2 (de) 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU1684400A (en) 1998-12-11 2000-07-03 Sankyo Company Limited Substituted benzylamines
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
BR9916567A (pt) 1998-12-23 2001-12-11 Searle Llc Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
US6458851B1 (en) 1998-12-23 2002-10-01 G. D. Searle, Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
IL143944A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
PT1140189E (pt) 1998-12-23 2003-09-30 Searle Llc Combinacoes de inibidores do transporte do acido biliar ileal e de derivados do acido fibrico para indicacoes cardiovasculares
KR20020000139A (ko) 1999-02-12 2002-01-04 추후제출 회장 담즙산 수송 및 타우로콜산염 흡수의 억제제로서의활성을 보유하는 신규한 1,2-벤조티아제핀
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
CZ290178B6 (cs) 1999-07-22 2002-06-12 Sankyo Company Limited Deriváty cyklobutenu
WO2001034570A1 (fr) 1999-11-08 2001-05-17 Sankyo Company, Limited Derives heterocycliques azotes
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
US6506921B1 (en) * 2001-06-29 2003-01-14 Virginia Tech Intellectual Properties, Inc. Amine compounds and curable compositions derived therefrom
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) * 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
SA04250066B1 (ar) 2008-09-22
UY28258A1 (es) 2004-11-30
KR101321577B1 (ko) 2013-10-25
EP1894564A3 (en) 2009-09-09
GB0307918D0 (en) 2003-05-14
IS8113A (is) 2005-11-01
DK1894564T3 (da) 2011-08-29
EP1894564A2 (en) 2008-03-05
CY1111995T1 (el) 2015-11-04
DE602004012079D1 (de) 2008-04-10
RU2008129204A (ru) 2010-01-27
PL1894564T3 (pl) 2011-11-30
AR043985A1 (es) 2005-08-17
JP2006522082A (ja) 2006-09-28
EP1610770A1 (en) 2006-01-04
TWI338577B (en) 2011-03-11
NZ542835A (en) 2009-01-31
CA2520109C (en) 2012-03-20
AU2004228731B2 (en) 2008-02-28
MXPA05010706A (es) 2005-12-12
WO2004089350A1 (en) 2004-10-21
NO20054369D0 (no) 2005-09-21
CN100366241C (zh) 2008-02-06
US20060199797A1 (en) 2006-09-07
EP1610770B1 (en) 2008-02-27
CN1771027A (zh) 2006-05-10
DK1610770T3 (da) 2008-05-13
ATE387194T1 (de) 2008-03-15
JP4870552B2 (ja) 2012-02-08
PT1610770E (pt) 2008-04-10
ES2368350T3 (es) 2011-11-16
SI1610770T1 (sl) 2008-06-30
US7514421B2 (en) 2009-04-07
EP1894564B1 (en) 2011-06-22
BRPI0408858A (pt) 2006-04-11
CY1107424T1 (el) 2012-12-19
JP2011173925A (ja) 2011-09-08
CO5640076A2 (es) 2006-05-31
RU2482850C2 (ru) 2013-05-27
RU2005128792A (ru) 2006-05-10
AU2004228731A1 (en) 2004-10-21
NO335140B1 (no) 2014-09-29
IL170913A (en) 2010-11-30
ATE513550T1 (de) 2011-07-15
JP5421326B2 (ja) 2014-02-19
RU2342928C2 (ru) 2009-01-10
CA2520109A1 (en) 2004-10-21
TW200505434A (en) 2005-02-16
SI1894564T1 (sl) 2011-08-31
PL1610770T3 (pl) 2008-07-31
NO20054369L (no) 2005-11-15
ES2299832T3 (es) 2008-06-01
MY137757A (en) 2009-03-31
HK1085666A1 (en) 2006-09-01
KR20050121241A (ko) 2005-12-26
DE602004012079T2 (de) 2009-02-26
ZA200507996B (en) 2007-04-25
PT1894564E (pt) 2011-07-26

Similar Documents

Publication Publication Date Title
UA84141C2 (ru) Применение ингибитора пктжк для лечения или профилактики запора
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
DE60112974D1 (en) Carbolinderivate
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
GB0101577D0 (en) Compounds
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
WO2004050030A3 (en) Anti-sickling agents
DE60216233D1 (en) Carbolinderivate
MXPA05006505A (es) Composiciones vaginales de sertaconazol.
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
TW200508199A (en) Novel compound
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
PL369772A1 (en) Compounds that inhibit factor xa activity
YU20902A (sh) Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima